Build status - In Progress

Study to Investigate Drug BIIB132 Administered to Adults With Spinocerebellar Ataxia 3

Spinocerebellar Ataxia 3 Study on Investigational Medication

Recruiting
18 years - 70 years
All
Phase 1
3 participants needed
1 Location

Brief description of study

The purpose of this research study is to learn more about a study drug that may affect patients with spinocerebellar ataxia type 3 (SCA3). This type of drug is called an antisense oligonucleotide. Eligible participants in this study will have the study drug injected into the fluid surrounding their spinal cord and brain through a fine needle placed in the spinal canal in the lower back. This procedure is called a lumbar puncture. After injection of the study drug, participants will be monitored in the hospital for 6 to 24 hours before going home. During the study, participants will receive study drug at up to 4 visits. Some of the assessments include: examinations of the brain and body, collection of blood, urine, and CSF (the fluid in the spine) samples, medical scans of the brain, and questionnaires about health and daily life.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Machado-Joseph disease, Spinocerebellar Ataxia
  • Age: 18 years - 70 years
  • Gender: All

This study investigates the effects of an investigational medication on adults with spinocerebellar ataxia type 3 (SCA3).

The focus of this study is to evaluate the safety and potential effects of the investigational medication on SCA3 symptoms. Researchers aim to understand how the medication interacts with the body and its impact on the condition.

  • Who can participate: The study is open to adults aged 18 and older diagnosed with spinocerebellar ataxia type 3.
  • Study details: Participants will receive the investigational medication through a procedure called a lumbar puncture. They will be monitored in the hospital for a period after each injection to ensure safety.
  • Study visits: The study requires 4 visits.
Updated on 04 Aug 2024. Study ID: 850137

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center